| pubmed-article:3013274 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3013274 | lifeskim:mentions | umls-concept:C0162409 | lld:lifeskim |
| pubmed-article:3013274 | lifeskim:mentions | umls-concept:C0080202 | lld:lifeskim |
| pubmed-article:3013274 | lifeskim:mentions | umls-concept:C0019683 | lld:lifeskim |
| pubmed-article:3013274 | lifeskim:mentions | umls-concept:C0456603 | lld:lifeskim |
| pubmed-article:3013274 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3013274 | pubmed:dateCreated | 1986-8-19 | lld:pubmed |
| pubmed-article:3013274 | pubmed:abstractText | 44% of 63 British patients with either haemophilia A or B were HTLV-III antibody positive (HTLV-VIII+). HTLV-III+ was more frequent in high factor VIII concentrate users and 75% of severely affected haemophilia A patients were HTLV-III+. All eight patients who were exposed to factor IX concentrate were HTLV-III-. 17 haemophilia A patients who received only British made factor VIII concentrate (average 12,000 units/year) were HTLV-III-. Two of 63 patients had evidence of a pre-AIDS type symptom complex and both were HTLV-III+. Information from a cohort of 21 Liverpool haemophiliacs suggests that HTLV-III was first introduced into this country in 1981. OKT4/T8 ratios were abnormal in 52% of 21 patients studied but this finding was not confined to either HTLV-III+ or HTLV-III- individuals. The spouses of 14 HTLV-III+ haemophiliacs were all HTLV-III-. | lld:pubmed |
| pubmed-article:3013274 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3013274 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3013274 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3013274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3013274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3013274 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3013274 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:3013274 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:3013274 | pubmed:author | pubmed-author:WinterMM | lld:pubmed |
| pubmed-article:3013274 | pubmed:author | pubmed-author:BarnetR JRJ | lld:pubmed |
| pubmed-article:3013274 | pubmed:author | pubmed-author:MachinS JSJ | lld:pubmed |
| pubmed-article:3013274 | pubmed:author | pubmed-author:McVerryB ABA | lld:pubmed |
| pubmed-article:3013274 | pubmed:author | pubmed-author:TurneyG JGJ | lld:pubmed |
| pubmed-article:3013274 | pubmed:author | pubmed-author:McCarthyKK | lld:pubmed |
| pubmed-article:3013274 | pubmed:author | pubmed-author:TedderR SRS | lld:pubmed |
| pubmed-article:3013274 | pubmed:author | pubmed-author:EvansPP | lld:pubmed |
| pubmed-article:3013274 | pubmed:author | pubmed-author:GallowayM JMJ | lld:pubmed |
| pubmed-article:3013274 | pubmed:author | pubmed-author:Cheingsong-Po... | lld:pubmed |
| pubmed-article:3013274 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3013274 | pubmed:volume | 63 | lld:pubmed |
| pubmed-article:3013274 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3013274 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3013274 | pubmed:pagination | 347-52 | lld:pubmed |
| pubmed-article:3013274 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:meshHeading | pubmed-meshheading:3013274-... | lld:pubmed |
| pubmed-article:3013274 | pubmed:year | 1986 | lld:pubmed |
| pubmed-article:3013274 | pubmed:articleTitle | HTLV-III antibody and T-cell subset ratios in haemophiliacs and their spouses. | lld:pubmed |
| pubmed-article:3013274 | pubmed:publicationType | Journal Article | lld:pubmed |
